NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 125,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 125,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the sale, the insider directly owned 69,302 shares in the company, valued at $1,864,916.82. The trade was a 64.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS traded up $0.49 during trading hours on Tuesday, reaching $27.34. The stock had a trading volume of 1,986,350 shares, compared to its average volume of 1,043,099. The business’s fifty day moving average is $30.58 and its two-hundred day moving average is $32.11. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -12.66 and a beta of 0.10. NewAmsterdam Pharma Company N.V. has a twelve month low of $23.05 and a twelve month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. Sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada dropped their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.73.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its stake in NewAmsterdam Pharma by 4,105.5% in the second quarter. California State Teachers Retirement System now owns 2,284,796 shares of the company’s stock worth $77,432,000 after purchasing an additional 2,230,467 shares in the last quarter. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after buying an additional 1,145,128 shares in the last quarter. Duquesne Family Office LLC raised its holdings in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares during the last quarter. Castle Hook Partners LP bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at about $38,062,000. Finally, Adage Capital Partners GP L.L.C. lifted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after buying an additional 1,062,359 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.